Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PRNP | P04156 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891921 | 0.88 | PRNP (0.47) | MEN1KMT2AAVPR1AHTTPRNP | |
| SCHEMBL25652595 | 0.86 | MEN1 (0.43) | MEN1KMT2AAVPR1AHTTPRNP | |
| SCHEMBL31253420 | 0.86 | MEN1 (0.43) | MEN1KMT2AAVPR1AHTTPRNP | |
| SCHEMBL25652536 | 0.82 | KMT2A (0.39) | MEN1KMT2AAVPR1AHTTPRNP | |
| SCHEMBL1757872 | 0.82 | MEN1 (0.49) | MEN1KMT2AAVPR1APTGESHTT | |
| SCHEMBL31253421 | 0.82 | MAPT (0.49) | MEN1KMT2APRNPNPC1CYP1A2 | |
| SCHEMBL25652545 | 0.82 | KMT2A (0.41) | MEN1KMT2AAVPR1AHTTPRNP | |
| Hydrochloric Acid SCHEMBL5756574 | 0.79 | KMT2A (0.54) | MEN1KMT2APRNPCYP1A2CYP3A4 | |
| SCHEMBL11826284 | 0.78 | MAPK1 (0.65) | MEN1KMT2AHTTKDM4ENPC1 | |
| SCHEMBL25221940 | 0.78 | PRNP (0.38) | MEN1KMT2AAVPR1AHTTPRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943635-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-17 | — | — | US | disclosed |
| US-20080255191-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | ANGIBAUD PATRICK RENE | 2008-10-16 | — | — | US | disclosed |
| EP-1322650-B1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7241777-B2 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1490065-B1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINONE AND QUINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-7196094-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7173040-B2 | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7067531-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-27 | — | — | US | disclosed |
| US-20050171111-A1 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6914066-B2 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-05 | — | — | US | disclosed |
| EP-1322650-A2 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| EP-1322636-A1 | FARNESYL TRANSFERASE INHIBITING 6- (SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119843-A1 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA, N.V. | 2003-06-26 | — | — | US | disclosed |
| EP-1140935-B1 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-14 | — | — | EP | disclosed |
| US-6458800-B1 | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-10-01 | — | — | US | disclosed |
| WO-2002024686-A2 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024683-A1 | FARNESYL TRANSFERASE INHIBITING 6-[(SUBSTITUTED PHENYL)METHYL]-QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024687-A1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
| EP-1140935-A2 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039082-A2 | 1,2-ANNELATED QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171111-A1 | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors | FNTA, FNTB, RCE1 | MEN1 1273/4885KMT2A 3132/4885AVPR1A 4115/4885 |
| US-20080255191-A1 | BENZYLIMIDAZOLYL SUBSTITUTED 2-QUINOLINE AND QUINAZOLINE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS | FNTA, FNTB, RCE1 | MEN1 1440/4885KMT2A 3036/4885AVPR1A 4237/4885 |
| US-20030119843-A1 | 1,2-annelated quinoline derivatives | NAT1, CYP7A1, CYP4A11 | MEN1 3167/4885KMT2A 2982/4885AVPR1A 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.